Lenvatinib is an oral multi-target tyrosine kinase inhibitor that inhibits the expression of VEGF and FGFR through multiple pathways, thereby preventing tumor angiogenesis, metastasis, and progression (11). Here, VEGFA is linked to neoplasm.